Key Takeaways Viatris' Q3 EPS of 67 cents beat estimates as revenues reached $3.76 billion, down 2% year over year.Branded drugs drove growth, offsetting weaker generics hit by FDA action at the Indore plant.Viatris raised 2025 guidance and added Japan rights via the Aculys Pharma acquisition.Viatris Inc. (VTRS) delivered third-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which beat the Zacks Consensus Estimate of 63 cents. The company recorded adjusted EPS of 75 cents in the year-ago quarter ...